In the tuberculosis context, it refers to aminoglucosides such as amikacin, capreomycin, kanamycin, or streptomycin, previously considered to be key MDR-TB regimen components (the term as used here does not include the second-line TB drugs imipenem and meropenem that are also given by injection).